The estimated Net Worth of Donna James is at least $3.11 Milión dollars as of 23 November 2021. Ms. James owns over 7,000 units of Boston Scientific stock worth over $1,663,693 and over the last 17 years she sold BSX stock worth over $1,128,580. In addition, she makes $319,979 as Independent Director at Boston Scientific.
Sign up
Ms. James BSX stock SEC Form 4 insiders trading
Donna has made over 4 trades of the Boston Scientific stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 7,000 units of BSX stock worth $399,210 on 23 November 2021.
The largest trade she's ever made was exercising 57,115 units of Boston Scientific stock on 8 July 2021 worth over $4,737,118. On average, Donna trades about 1,028 units every 36 days since 2007. As of 23 November 2021 she still owns at least 20,059 units of Boston Scientific stock.
You can see the complete history of Ms. James stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Donna James biography
Donna Anita James serves as Independent Director of the Company. Ms. James is the founder of Lardon & Associates LLC, a business development and executive advisory services firm, where she has served as president and managing director since April 2006. Ms. James has more than 30 years of diverse management and leadership experience, including her experience at Nationwide Insurance and Financial Services, beginning in 1981. In her 25 years at Nationwide, she served in several leadership roles, including president of Nationwide Strategic Investments, a division of Nationwide Insurance Company, from 2003 to 2006, at which time she had direct responsibility for developing and executing strategies for several U.S. and global financial services subsidiaries and affiliates. Ms. James also is the founder of The Center for Healthy Families, a non-profit in Columbus, Ohio, and the former chair of the National Women's Business Council by presidential appointment. Ms. James currently serves as a director of the FIS Group, a privately held asset management and investment advisory firm. She formerly served as a director of Time Warner Cable Inc. and Marathon Petroleum, Inc., where she is currently serving as a board advisor.
What is the salary of Donna James?
As the Independent Director of Boston Scientific, the total compensation of Donna James at Boston Scientific is $319,979. There are 13 executives at Boston Scientific getting paid more, with Michael Mahoney having the highest compensation of $15,764,100.
How old is Donna James?
Donna James is 62, she's been the Independent Director of Boston Scientific since 2015. There are 6 older and 23 younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.
Insiders trading at Boston Scientific
Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele a Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.
What does Boston Scientific do?
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
What does Boston Scientific's logo look like?
Complete history of Ms. James stock trades at American Electric Power, Boston Scientific, CNO Inc, Hartford Services, Landbridge, Marathon Petroleum Corp a Victoria's Secret & Co
Boston Scientific executives and stock owners
Boston Scientific executives and other stock owners filed with the SEC include:
-
Michael Mahoney,
Chairman of the Board, President, Chief Executive Officer -
Daniel Brennan,
Chief Financial Officer, Executive Vice President -
Joseph Fitzgerald,
Executive Vice President, President, Interventional Cardiology -
Edward Mackey,
Executive Vice President - Operations -
David Pierce,
Executive Vice President and President, MedSurg and President, Endoscopy -
Michael F. Mahoney,
Chairman, Pres & CEO -
Daniel J. Brennan,
Exec. VP & CFO -
Joseph M. Fitzgerald,
Exec. VP & Pres of Interventional Cardiology -
Edward F. Mackey,
Exec. VP of Global Operations -
Jeffrey B. Mirviss,
Exec. VP & Pres of Peripheral Interventions -
Edward Ludwig,
Lead Independent Director -
Charles Dockendorff,
Independent Director -
David Roux,
Independent Director -
John Sununu,
Independent Director -
Donna James,
Independent Director -
Nelda Connors,
Independent Director -
Ellen Zane,
Independent Director -
Stephen MacMillan,
Independent Director -
Yoshiaki Fujimori,
Independent Director -
John Sorenson,
Senior Vice President - Manufacturing and Supply Chain -
Meghan Scanlon,
Senior Vice President and President, Urology and Pelvic Health -
Scott Olson,
Senior Vice President and President, Rhythm Management -
Maulik Nanavaty,
Senior Vice President and President - Neuromodulation -
Wendy Carruthers,
Senior Vice President - Human Resources -
Desiree Ralls-Morrison,
Senior Vice President, General Counsel, Corporate Secretary -
Jodi Eddy,
Senior Vice President, Chief Information Officer -
Eric Thepaut,
Executive Vice President and President - Europe, Middle East and Africa -
Jeffrey Mirviss,
Executive Vice President and President - Peripheral Interventions -
Ian Meredith,
Executive Vice President, Global Chief Medical Officer -
Arthur Butcher,
Executive Vice President and President, Asia Pacific -
Catherine Jennings,
VP of Global Marketing & New Bus. Devel. of Peripheral Interventions -
Vance R. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Susan Vissers Lisa,
VP of Investor Relations -
Jodi Euerle Eddy,
Sr. VP and Chief Information & Digital Officer -
Jonathan R Monson,
VP, Global Controller & Chief Accounting Officer -
Vance R Brown,
SVP, GC and Corp. Secretary -
Timothy A. Pratt,
EVP & General Counsel -
Supratim Bose,
EVP & President, Asia-Pacific -
Michael P. Phalen,
SVP & President, Endoscopy -
Keith D Dawkins,
Sr. VP, Chief Medical Officer -
Kevin J. Ballinger,
EVP & Pres, Interven Cardio -
Cheryl Pegus,
Director -
David S Wichmann,
Director -
Xin Warren Wang,
SVP and Pres, Asia Pacific -
Peter M Nicholas,
Director -
Kristina M Johnson,
Director -
Nicholas J Jr Nicholas,
Director -
Karen Prange,
SVP&Pres, Uro & Women's Health -
Ernest Mario,
Director -
John E Abele,
Director -
Uwe E Reinhardt,
Director -
Katharine T Bartlett,
Director -
Jean Fitterer Lance,
SVP & Chief Compliance Officer -
Kenneth Pucel,
EVP, Operations -
Bruce L Byrnes,
Director -
John Michael Onuscheck,
SVP & Pres-Neuromodulation -
Jeffrey D Capello,
Chief Accounting Officer -
Otha T. Iii Spriggs,
SVP, Human Resources -
William Kucheman,
SVP & Group President -
John Raymond Elliott,
Director -
Lawrence R Neumann,
SVP and Pres, Emerging Markets -
John B. Pedersen,
Pres,Uro & Women's Health -
Brian R Burns,
SVP - Quality -
Ray J Groves,
Director -
Sam R Leno,
CFO & EVP Finance & IS -
Stephen F Moreci,
Sr. VP, Endosurgery -
Marye Anne Fox,
Director -
Fred Colen,
EVP -
John E Pepper,
Director -
James Gilbert,
EVP -
Donovan Paul,
SVP, Corporate Comm -
David W Mc Faul,
Senior VP International -
Ursula M Burns,
Director -
Warren B Rudman,
Director -
William F Jr Mcconnell,
SVP, Administration CRM -
Donald S Baim,
EVP, Chief Med. & Sci. Officer -
Lucia Luce Quinn,
Exec. Vice President-HR -
James R Tobin,
President & CEO -
Paul W Sandman,
EVP and General Counsel -
Paul A Laviolette,
COO -
Nancy Ann Deparle,
Director -
Joel Lawrence Fleishman,
Director -
David C Habiger,
Director -
Jonathan Monson,
SVP, Global Controller and CAO -
Emily Woodworth,
SVP, Global Controller and CAO -
Jessica L Mega,
Director -
Susan E Morano,
Director